Skip to content
2000
Volume 2, Issue 3
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Inhibition of the blood fibrinolytic system (plasminogen/plasmin) occurs either at the level of plasminogen activators, regulated by specific plasminogen activator inhibitors (PAIs) or at the level of plasmin, mainly regulated by α2-antiplasmin (α2-AP). In this contribution, we focused on the roles of α2-AP in acute myocardial infarction and vascular remodeling associated with cardiovascular diseases. Our findings have identified a new target for the development of new therapeutics for the clinical therapy of cardiovascular diseases.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180053765129
2005-05-01
2025-05-24
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180053765129
Loading

  • Article Type:
    Review Article
Keyword(s): antiplasmin; myocardial infarction; re-endothelialization; vegf; vegfr-1
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test